tapebrief

DGX · Q2 2025 Earnings

Bullish

Quest Diagnostics

Reported July 22, 2025

30-second summary

Quest delivered revenue of $2.76B (+15.2% YoY, including +5.2% organic) and adjusted EPS of $2.62, with requisition volume up 16.3% (2.1% organic) reflecting the LifeLabs contribution plus genuine organic acceleration. Management raised FY2025 guidance across revenue, adjusted EPS, and operating cash flow on the back of "continued utilization trends" — the kind of mid-year raise Quest rarely makes without conviction. The setup for the back half hinges on Project Nova investment timing (most modernization spend lands in H2) and PAMA, which management sized at roughly $100M of exposure if no fix or delay materializes.

Headline numbers

EPS

Q2 FY2025

$2.62

Revenue

Q2 FY2025

$2.76B

+15.2% YoY

Gross margin

Q2 FY2025

34.1%

Free cash flow

Q2 FY2025

$0.32B

Operating margin

Q2 FY2025

15.9%

Key financials

Q2 FY2025
MetricQ2 FY2025YoY
Revenue$2.76B+15.2%
EPS$2.62—
Gross margin34.1%—
Operating margin15.9%—
Free cash flow$0.32B—

Guidance

Prior quarter data unavailable — comparison not possible.

Segment KPIs

Q2 FY2025
SegmentQ2 FY2025YoY
Diagnostic Information Services$2.699B+15.7%

Other KPIs

Q2 FY2025
SegmentQ2 FY2025
Requisition Volume Growth16.3%
Organic Requisition Volume Growth2.1%
Revenue Per Requisition Change-0.4%
Operating Margin (Reported)15.9%
Operating Margin (Adjusted)16.9%
Operating Cash Flow (YTD)$858M

Management tone

Management raised the FY guide mid-year — uncharacteristic for Quest, which typically prefers incremental quarterly adjustments. The quote anchoring the shift: "Given our performance in the quarter and continued utilization trends, we're raising our full year 2025 guidance." Conviction in demand sustainability appears to have moved from "tracking" to "confirmed."

The hospital channel narrative pivoted from defensive to offensive. Management framed hospital financial pressures and lab technologist shortages as a tailwind: "As hospitals grapple with financial pressures and shortages of skilled lab technologists, they are choosing Quest to access our best-in-class expertise, innovation, and efficiency instead of running their own labs." This is no longer about defending share against in-house labs — it's about taking work as hospitals retreat.

The consumer channel crossed from experiment to scaled engine. The disclosure of one million customer orders since the platform's 2022 launch is a deliberate scale milestone: "We recently fulfilled our one millionth customer order since launching this enhanced online platform in the fall of 2022." Management is signaling the DTC channel deserves to be modeled, not dismissed.

Automation moved from roadmap to deployment. Front-end automation is now installed at six sites and the automated accessioning pilot at Clifton Lab is complete, with rollout across the network planned through 2026. The language shifted from "investing in" to "rolling out," which is meaningfully more concrete.

Recurring themes management leaned on this quarter:

Advanced diagnostics driving organic growth in five clinical focus areasAcquisitions as material revenue contributor complementing organic growthAutomation and AI deployment for operational efficiency and cost reductionConsumer channel expansion and direct-to-consumer scalingHospital and physician channel optimization through collaborative solutionsEnterprise account expansion and large customer penetration

Risks management surfaced:

Wage increases impacting margin expansionHigher interest expense on earningsTariff impacts currently in place, primarily in Europe and ChinaProject Nova investment execution risk in second half of 2025Hospital financial pressures and lab technologist shortages creating competitive dynamics

Q&A highlights

Anne Hines · Mississippi Securities

How should Quest view the impact of the 'One Beautiful Bill' potentially causing 10 million uninsured over the next decade, and what are management's thoughts on PAMA going into 2026?

Management quantified the bill's impact as ~1.5% of total U.S. healthcare spend. Estimated Medicaid impact is immaterial in 2026 and very small in 2027 due to state transition timing. Exchange impact estimated at 30-40 basis points on volume in 2026, affecting only 4-5% of current revenue. On PAMA, management is pursuing dual strategy: reform legislation (introduced to three committees, expected to become bill in summer) and contingency sixth delay.

One Beautiful Bill removes $1 trillion of $62 trillion projected spend over 10 years (~1.5%)No material Medicaid impact in 2026, immaterial in 2027Exchange represents 4-5% of current revenueEstimated 30-40 basis point volume impact in 2026 from exchange

Kevin Caliendo · UBS

Are modernization investments still expected to total 20 cents for the full year given some pulled forward into Q2, and will the company achieve margin expansion in the second half despite these investments?

Management confirmed 20 cents target for modernization expenses plus QRA expenses. Most modernization spending expected in second half (bulk not yet incurred in first half). Reaffirmed full-year operating margin expansion despite investment timing.

Modernization expenses target: ~20 cents for full yearQRA expenses also occurring in 2025Minimal modernization expenses in first half; bulk in second halfFull-year operating margin expansion still expected

Elizabeth Anderson · Evercore ISI

Of the 30 basis point exchange impact, what utilization assumptions are embedded for the uninsured population, and how might increased uninsured volume offset the legislative headwinds?

Management noted uninsured represents very small portion of current revenue. Of exchange lives expected to drop, 65-70% assumed to find alternatives (higher premiums, employer plans). Only minority expected to go uninsured. Emphasized exchange population has income by definition (not Medicaid-eligible) and will likely retain coverage through alternative means.

65-70% of exchange dropouts expected to find alternative coverageExchange population by definition has income and employmentUninsured utilization is minimal portion of revenue today30 basis point volume impact in 2026 reflects conservative assumptions

Erin Wright · Morgan Stanley

How are utilization trends progressing into Q3, and can management parse out underlying utilization trends versus market share gains?

Q2 showed strong utilization with uptick from Q1, driven by expanded access (Elevance, Sentera networks; 1M new lives in NV, CO, WV, GA), advanced diagnostic tests (AB4240 Alzheimer's, cardiometabolic), and weather recovery. Q3 utilization tracking consistent with Q2, driven by access expansion and strong advanced diagnostics. Strong test-per-requisition improvement noted.

1 million new lives gained through Elevance/Sentera network access effective January 1Advanced diagnostics (AB4240, cardiometabolic) showing strong growthQ3 utilization consistent with Q2 trendMix of access expansion and market share gains driving growth

Patrick Donnelly · Citi

What is the expected cadence for Q3 margins and earnings, and what is the financial impact of PAMA and potential offsets?

Q2 is typically strongest quarter for margins/earnings; Q3 usually steps down slightly from Q2, Q4 steps down from Q3, Q1 weakest. PAMA impact sized at ~$100 million if no permanent fix or delay obtained. Management will take offsetting actions but unable to offset majority of impact.

PAMA pricing impact: approximately $100 million if no delay or permanent fixTypical quarterly pacing: Q2 strongest, Q3 slight step down, Q4 further decline, Q1 weakestManagement will offset 'a portion' of PAMA impact (unquantified)Unable to offset majority of $100 million negative impact

What to watch into next quarter

Organic revenue growth holding at/above 5.2%: with FY embedded organic of 3.5–4.0%, Q2's 5.2% sets a high bar. Whether Q3 sustains this is the cleanest read on demand.

Organic requisition growth above 2.1%: this quarter marked an inflection from acquisition-dependent to genuinely organic volume growth.

PAMA resolution path: reform legislation expected to become a bill in summer 2025. Watch for committee progress; absent a fix or sixth delay, ~$100M is at stake in 2026 with limited offsets disclosed.

H2 operating margin trajectory: Project Nova spend concentrates in H2 while management reaffirmed FY adjusted margin expansion vs. prior year. Q3 adjusted operating margin will test whether that math holds.

LifeLabs integration milestones: with M&A contribution still material to reported growth, watch for any disclosure on cost synergies or run-rate margin from the deal.

DTC scale disclosures: management chose to quantify 1M cumulative consumer orders this quarter. Watch whether they begin disclosing periodic DTC revenue or order growth.

Sources

  1. Quest Diagnostics Q2 FY2025 press release (SEC filing): https://www.sec.gov/Archives/edgar/data/1022079/000102207925000172/dgx063020258-kex991.htm
  2. Quest Diagnostics Q2 FY2025 earnings call transcript (prepared remarks and Q&A).

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.